Daiichi Sankyo Records Significant Loss Due to ADC Supply ‘Miscalculation’ Despite Strong Enhertu Sales, Raising Risk Management Questions

東洋経済オンライン Japan

Overview

Japanese pharmaceutical giant Daiichi Sankyo reported a substantial operating profit decrease for FY2025 despite record sales, attributing a 169.5 billion yen loss provision to compensation for Antibody-Drug Conjugate (ADC) Contract Manufacturing Organizations (CMOs). This ‘miscalculation’ in ADC supply planning, stemming from complex manufacturing and stringent long-term CMO contracts, highlights critical challenges in managing intricate ADC supply chains and raises questions about the company’s risk management and disclosure practices, despite robust sales of its flagship ADC, Enhertu.

In Depth

Background

Antibody-Drug Conjugates (ADCs) represent a groundbreaking modality in cancer treatment, delivering cytotoxic payloads selectively to cancer cells via specific antibodies, thereby revolutionizing oncology care. Daiichi Sankyo’s ‘Enhertu’ (trastuzumab deruxtecan) has been a global success, driving significant revenue due to its high efficacy. However, ADC manufacturing is exceptionally complex, requiring multiple intricate steps including the synthesis of the antibody, drug payload, and linker, followed by their conjugation. This demands highly specialized technical expertise and stringent quality control. Consequently, the number of Contract Manufacturing Organizations (CMOs) capable of ADC production is limited globally, making long-term manufacturing agreements common for pharmaceutical companies, often including minimum purchase obligations.

Key Findings / Results

In its consolidated financial results for fiscal year 2025, announced on May 11, 2026, Daiichi Sankyo reported record-high revenue of 819.5 billion yen, a 25.8% increase year-on-year, demonstrating the continued strong performance of ‘Enhertu.’ Despite this robust sales growth, the company recorded a significant 31% decrease in operating profit compared to the previous year. The primary cause of this substantial profit reduction was the booking of a massive loss provision of 169.5 billion yen for compensation to its Antibody-Drug Conjugate (ADC) Contract Manufacturing Organizations (CMOs).

According to the article, this loss stemmed from a “miscalculation” in Daiichi Sankyo’s ADC supply plan. Given the complexity of ADC manufacturing, long-term contracts with a limited number of global CMOs typically include minimum purchase obligations. Daiichi Sankyo reportedly failed to maintain its originally projected manufacturing volumes, leading to a breach of contract and subsequent compensation payments to the CMOs. This incident critically highlighted how complex and unpredictable the management of the ADC manufacturing supply chain can be, especially for highly potent drug products.

Technical Significance & Outlook

The booking of this substantial loss represents a major financial blow to Daiichi Sankyo and simultaneously raises questions regarding the company’s risk management framework and information disclosure practices. It underscores the lesson that shortcomings in supply chain management can directly impact a company’s profitability, despite strong commercial success like that of Enhertu. Moving forward, Daiichi Sankyo will likely need to revisit its contract terms with ADC manufacturing CMOs, improve the accuracy of its demand forecasting, and enhance the flexibility of its supply strategy.

Moreover, this issue raises broader questions for the entire industry regarding the industrialization challenges of the ADC modality. While specialized facilities and expertise are essential for ADC manufacturing, and partnerships with CDMOs are indispensable, this incident re-emphasizes the critical importance of balancing contract terms and risk sharing. As pharmaceutical companies build robust ADC pipelines, establishing a resilient and flexible manufacturing and supply system will be a crucial factor determining future competitive advantage. This case serves as a poignant reminder of the paramount importance of advanced supply chain management in biopharmaceutical manufacturing.